Jakob Körbelin

Jakob Körbelin is a Principal Investigator at the University Medical Center Hamburg-Eppendorf (UKE), affiliated with the Faculty of Medicine and the II. Medical Clinic and Polyclinic. His research focuses on vascular biology, gene therapy, and neurological disorders, particularly targeting the blood-brain barrier using adeno-associated viral (AAV) vectors. He leads studies on pulmonary hypertension, neurovascular interactions, and genetic diseases like Niemann-Pick type C2. His work bridges basic science and translational medicine, emphasizing AAV engineering and therapeutic applications.

Key research interests include endothelial cell biology, neuroinflammation, and the pathophysiology of vascular diseases. Notably, he received the UCCH Hubertus Wald Young Investigator Award 2013 for his contributions. His lab explores mechanisms of vascular dysfunction, gene delivery optimization, and the impact of viral vectors in treating rare diseases. Collaborations span molecular neurobiology, immunology, and translational oncology.

Publications highlight breakthroughs in AAV-mediated therapies, such as reversing neurodegeneration in NPC2 models and identifying novel targets for pulmonary hypertension. Ongoing projects address microvascular brain pathology in SARS-CoV-2 infection and the role of transcription factors in vascular diseases.